GeneVentiv Therapeutics Moves Forward with GENV-HEM Gene Therapy for Hemophilia A After Positive FDA Feedback GeneVentiv Therapeutics has received positive feedback from the FDA regarding its GENV-HEM gene therapy, paving the way for advancements in treatments for Hemophilia A.

GeneVentiv Therapeutics Moves Forward with GENV-HEM Gene Therapy for Hemophilia A After Positive FDA Feedback #USA #Raleigh #Hemophilia_A #GeneVentiv #GENV-HEM

GeneVentiv Therapeutics Secures NHLBI Funding for Hemophilia A Therapy GeneVentiv Therapeutics has been selected for the NHLBI Catalyze Program, enabling funding for its GENV-HEM gene therapy research, promising advances in hemophilia A treatments.

GeneVentiv Therapeutics Secures NHLBI Funding for Hemophilia A Therapy #United_States #Raleigh #GeneVentiv #GENV-HEM #NHLBI

GeneVentiv Sets Milestone with Global License for Novel Gene Editing Therapy in Pompe Disease Treatment GeneVentiv Therapeutics has secured a groundbreaking global licensing agreement for GENV-002, a universal gene editing therapy for Pompe disease, promising new hope for patients.

GeneVentiv Sets Milestone with Global License for Novel Gene Editing Therapy in Pompe Disease Treatment #United_States #Raleigh #GeneTherapy #GeneVentiv #PompeDisease